눈에 묻으면 몇 분간 물로 조심해서 씻으시오. 가능하면 콘택트렌즈를 제거하시오. 계속 씻으시오.
P308+P313
노출 또는 접촉이 우려되면 의학적인 조치· 조언를 구하시오.
P321
(…) 처치를 하시오.
P332+P313
피부 자극이 생기면 의학적인 조치· 조언을 구하시오.
P362
오염된 의복을 벗고 세척 후에 재사용하기
P405
밀봉하여 저장하시오.
P501
...에 내용물 / 용기를 폐기 하시오.
NFPA 704
0
2
0
이바카프토 C화학적 특성, 용도, 생산
개요
In January 2012, the US FDA approved ivacaftor for the treatment of cystic
fibrosis (CF) in patients who have the G551D mutation of the CF transmembrane regulator (CFTR) and are at least 6 years old. Ivacaftor (also known as VX-770) is a CFTR potentiator that increases the open probability of CFTR, thus increasing chloride
secretion particularly in the 5% of CF patients with the G551D/F508 gating/
processing mutation. Ivacaftor was discovered by medicinal chemistry optimization of a lead scaffold identified through high-throughput screening of a 228,000 compound collection. In cultured bronchial epithelial cells from a CF patient with F508del, ivacaftor increased chloride secretion
(EC50=81 nM). Preparation of ivacaftor is accomplished via a multistep
synthesis oftwointermediates, 4-oxo-1,4-dihydroquinoline-3-carboxylic acid
and 5-amino-di-tert-butylphenyl methyl carbonate, which are coupled using
propane phosphonic acid anhydride (T3P) to afford the amide; deprotection of
the phenol then provides ivacaftor.
용도
Ivacaftor (VX-770, Kalydeco) is a potentiator of CFTR targeting G551D-CFTR and F508del-CFTR with EC50 of 100 nM and 25 nM, respectively
정의
ChEBI: An aromatic amide obtained by formal condensation of the carboxy group of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid with the amino group of 5-amino-2,4-di-tert-butylphenol. Used for the treatment of cystic fibrosis.
Clinical Use
Vertex’s ivacaftor was granted breakthrough therapy designation by the FDA in January 2012 for
cystic fibrosis (CF) patients who bear the G551D mutation in the Cycstic Fibrosis Transmembrane
Regulator (CFTR) gene. This CFTR mutation occurs in roughly 4% of the 30,000 people living with
CF in the United States. While the compound has been identified as a potentiator in cell-based assays,
its mechanism of action is as yet unknown.